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Abstract
Background:  Diabetes mellitus has become a major health issue in the United States and
contributes to morbidity and mortality from coronary artery disease. Despite lifestyle changes and
medications that have been shown to decrease complications and death, many persons have poor
glycemic control. The purpose of this study is to determine the prevalence of elevated Hemoglobin
A1c levels, a marker of glycemic control in patients presenting for coronary artery bypass surgery,
and to determine if risk factors for diabetes mellitus could identify those patients with an elevated
hemoglobin A1c.
Methods: All patients undergoing coronary artery bypass surgery had hemoglobin A1c levels
determined immediately preoperatively. Proportions were used to describe the number of patients
with elevated levels. Linear regression and receiver operator characteristic curves were used to
evaluate the accuracy of risk factors to identify patients with elevated levels.
Results: 83 of 87 (95%) diabetic patients had elevated A1c levels (≥ 6.0%), with 55 of 87 (63%)
having inadequate control – A1c levels ≥ 7.0. 93 of 163 (57%) non-diabetic patients had elevated
A1c levels (≥ 6.0%), with 19 (12%) having levels ≥ 7.0%. Risk factors for diabetes mellitus poorly
predicted which patient had elevated A1c levels.
Conclusion: The prevalence of elevated hemoglobin levels in patients undergoing coronary artery
bypass surgery is high and routine measurement should be done to permit institution of lifestyle
modifications and medication changes that decrease complications and death from diabetes
mellitus.
Background
The prevalence of diabetes mellitus(DM) is increasing in
the United Sates and has become a major public health
issue [1]. Nearly 21 million Americans – 7% of the popu-
lation – have DM, including over 6 million who are undi-
agnosed [1]. Additionally, there are 41 million Americans
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with pre-diabetes [2]. DM is a risk factor for coronary
artery disease and its presence portends a worse outcome
– both short and long term – in patients undergoing cor-
onary artery bypass surgery [3,4]. Following recent studies
that have shown the benefits of tight glycemic control in
both diabetic and non-diabetic patients [5,6], we insti-
tuted protocols designed for tight glycemic control in
both the intensive care unit and the stepdown unit. We
noticed, however, that some patients without any history
of DM were still requiring antiglycemic therapy upon dis-
charge and that other patients with a history of DM
remained poorly controlled despite resumption of their
usual antiglycemic medicines and eating a hospital pro-
vided diabetic diet. To better help us provide for patients'
post-discharge care, we began to routinely check hemo-
globin A1c (HbA1c). HbA1c is the glycosolated form of
hemoglobin and its level is proportional to the average
glucose level over the past 2–3 months [7]. While not rec-
ommended for the diagnosis of DM [8], specific HbA1c
levels are recommended as treatment goals by national
organizations [9,10] and we used these levels in guiding
post-discharge therapy and instructions. The purpose of
this study was to determine the prevalence of elevated
HbA1c in the diabetic and non-diabetic subcohorts of a
cardiac surgery population and to determine if age,
height, weight, and body mass index – standard risk fac-
tors for DM could be used to predict elevated HbA1c lev-
els.
Methods
This retrospective study was approved on August 30, 2007
by the St. Vincent Mercy Medical Center Review Board,
which waived informed consent. HbA1c levels had been
drawn immediately prior to surgery in all patients under-
going cardiac surgery as part of their routine care and the
results included in our computerized database. Data are
presented as histograms, proportions, and means ± stand-
ard deviation and analyzed with student t test and Chi
square test. We separately used linear regression on
patients with and without DM to predict HbA1c levels
based on age, height, weight, and body mass index. Then
we used receiver operator characteristic curves to measure
the predictive accuracy of the two linear regressions. The
results are given as area under the receiver operator char-
acteristic curve (c-statistic ± standard error). SPSS 13.0
(SPSS, Inc., Chicago, IL) was used for data analysis. The
power analysis was based on determining the 95% confi-
dence interval for the point estimate within 5% of the true
proportion of patients with elevated HbA1c – defined as ≥
6.0% – assuming the true proportion was 0.2. This
required 250 patients [11].
Results
Data were collected from 250 consecutive patients under-
going CABG (January 2007 – July 2007) in whom preop-
erative HbA1c was measured. Of these patients, 212
underwent isolated CABG surgery and the other 38 CABG
combined with carotid, valve, or aortic surgery. The pro-
portion of patients with DM was similar in the two
groups. Patients were 65 ± 11 years of age, weighed 88 ±
20 kg, were 172 ± 20 cm tall, and had body mass index
(BMI) 30 ± 6. One hundred seventy seven (71%) of the
patients were male and 87 (35%) patients had diabetes
mellitus – 13 were receiving insulin at home, 59 oral
hypoglycemic agents, 5 both, and 10 neither.
The distribution of HbA1c values are shown for the dia-
betics and non-diabetics in Figure 1. Diabetic patients had
higher levels (8.0 ± 2.0% v. 6.2 ± 0.9%, p < .001) than
non-diabetic patients. Sixty four percent (95% confidence
interval = 58–72%) of the patients had A1c ≥ 6.0%. Only
four (5%) of the diabetic patients had HbA1c in the nor-
mal range (HbA1c < 6.0%) and another 28 (32%) had
HbA1c levels that met the ADA goal of < 7.0%. The
remaining 55 (63%) had unacceptably high levels, with
12 (14%) having levels ≥ 10%. Over half (n = 93, 57%) of
the patients without a history of diabetes mellitus had ele-
vated HbA1c ≥ 6.0% with 19 (12%) of them having
HbA1c ≥ 7.0%. In patients with DM, the standard risk fac-
tors of age, height, weight, and body mass index poorly
predicted elevated HbA1c: c-statistic = .639 ± .064, p =
.027 for HbA1c ≥ 7.0% and c-statistic = .470 ± .204, p =
.839 for HbA1c ≥ 6.0%. In non-diabetic patients, results
were c-statistic = .742 ± .048, p < .001 for HbA1c ≥ 7.0%
and c-statistic = .615 ± .045, p = .013 for HbA1c ≥ 6.0%.
Discussion
We found that many patients with a history of diabetes
mellitus undergoing CABG had elevated HbA1c levels
suggesting poor glycemic control. Additionally, we found
that over half of the non-diabetic patients undergoing
CABG had elevated HbA1c levels suggestive of prediabetes
or diabetes mellitus. Standard risk factors of age, height,
weight, and body mass index were inadequate predictors
of elevated HbA1c and should not be used instead of
HbA1c as a screening test in CABG patients.
One previous study has evaluated A1c levels in diabetic
patients undergoing CABG. Cohen et al. found that A1c
levels were 7.03 ± 1.50% and were associated with
increased risk of complications in an Israeli population
[4]. They did not evaluate non-diabetic patients. We
found higher A1c levels (8.0 ± 2.0%) in our diabetic pop-
ulation. Further study is needed to determine the reasons
for the poorer control in Ohio patients than in Israeli
patients. A study in non-diabetic patients undergoing per-
cutaneous coronary interventions (PCI) found a 30%
prevalence of elevated (≥ 6.0%) A1c levels and another
3% had A1c levels ≥ 7.0% and that levels ≥ 6.% were
related to a worse 12 month outcome [12]. Our higherJournal of Cardiothoracic Surgery 2008, 3:63 http://www.cardiothoracicsurgery.org/content/3/1/63
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rate (57% ≥ 6.0% and 12% ≥ 7.0%)of abnormal A1c lev-
els may indicate more extensive disease that would neces-
sitate CABG instead of PCI. Kowalska et al. found that A1c
levels were positively associated with number of diseased
vessels [13].
DM is associated with organ damage to the nerves, eyes,
kidneys, blood vessels, and heart leading to morbidity,
decreased quality of life, and increased mortality [9].
While a prospective, randomized trial of tight glycemic
control in patients with type 1 DM has shown a 57% risk
reduction in cardiovascular events over a mean followup
of 17 years [14], long-term prospective studies evaluating
tight control in type II DM have not shown such impres-
sive results. However, the UK Prospective Diabetes Study
Group has shown that intensive control with antiglycemic
agents compared to conventional therapy is associated
with a lowering of myocardial infarction risk that is of
"borderline significance" of 14% and that the use of met-
formin is associated with a lower risk of death in over-
weight diabetic patients [15,16]. Improved glycemic
control regardless of method was associated with a low-
ered risk of myocardial infarction [17]. A recent meta-
analysis found that each 1% lowering of HBA1c was asso-
ciated with a 18% reduction in relative risk of developing
cardiovascular disease [18].
In a nationwide survey only half of patients with DM met
American Diabetes Association clinical practice recom-
mendation of HbA1c < 7% and 30% had HbA1c ≥ 8%
[19]. Studies have shown that lifestyle modification, such
as weight loss, dietary changes, and exercise decease the
likelihood of developing DM [20,21]. Although cardiac
surgery is a major life stressor it is also an opportunity for
health care professionals to intervene and educate
patients and to institute therapy for secondary prevention
of disease. Smoking cessation and low-fat diets are com-
mon lifestyle interventions in patients undergoing cardiac
surgery. Antihypertensives, lipid lowering drugs, such as
statins, and aspirin are commonly started or adjusted for
better control in patients who have undergone CABG.
Histogram showing the distribution of hemoglobin A1c levels in patients with and without diabetes mellitus undergoing CABG  surgery Figure 1
Histogram showing the distribution of hemoglobin A1c levels in patients with and without diabetes mellitus 
undergoing CABG surgery. The dashed curve (patients without diabetes mellitus) and solid curve (patients with diabetes 
mellitus) show the expected normal distribution for these populations.
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While the association with glucose intolerance and coro-
nary artery disease is well described [22], our study is the
first to show the high prevalence in patients undergoing
CABG of undiagnosed prediabetes or diabetes mellitus
and poorly controlled glycemia in patients with known
diabetes mellitus. Given the benefits that may be achieved
by tighter glycemic control [15-18,20,21], screening of all
patients undergoing CABG is recommended. Studies are
needed to determine if CABG surgery should be delayed
to lower the A1c level and to determine the level to which
it should be lowered.
While not all patients with elevated HbA1c have DM – the
diagnosis should be made on the basis of fasting glucose
levels and glucose tolerance test, they are all, at least, at
increased risk for developing DM. At the minimum, we
recommend lifestyle changes of weight loss, diet changes,
and exercise. All patients with elevated HbA1c should fol-
lowup with their primary care physician or endocrinolo-
gist for further diagnostic evaluation. For patients still
requiring insulin to control hyperglycemia at time of hos-
pital discharge, we recommend discharge with an appro-
priate individualized antihyperglycemic medicine.
Diabetic patients with an elevated HbA1c are also given
similar counseling and adjustments made, if necessary, in
their usual diabetic medications.
The limitation of this study is that it was conducted at one
hospital, which may limit its generalizabilty. Patients in
other areas of the country may have different prevalences
of DM and risk factors for DM and this study needs to be
validated in other geographical regions. The prevalence of
DM in Ohio, 7.5%, is similar to the prevalence (7.3%) in
the United States, which suggests that our findings of ele-
vated HbA1c in 57% of nondiabetic patients undergoing
CABG would hold true elsewhere in the United States
[23].
In conclusion, we found that 57% of non-diabetic
patients undergoing CABG had elevated HbA1c. Addi-
tionally, 96% of diabetic patients undergoing CABG had
elevated HbA1c. These high prevalences of elevated
HbA1c suggest routine evaluation in all adult patients
undergoing CABG in order to institute lifestyle and medi-
cation changes that improve glycemic control.
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